Postmenopausal osteoporosis (OVX) rat model: After 12 weeks of AOD 9604 treatment, the number of osteoclasts decreased by 35%, CTX levels decreased by 40%, and bone resorption rate decreased by 50%
The two primary endpoints were the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS, which ranges from 0 to 100) and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
See Table 12-8 for combination products
Product Details & Usage Pack Size: 5 vials 4 mL each (Total 20 mL) Form: Lightweight, fast-absorbing ampoule serum Application Methods: Topical: Apply 23 drops to cleansed face and gently massage until absorbed
Existing reviews have further highlighted that pharmacokinetic and safety characterization in humans remains incomplete, complicating clinical counseling regarding timing of discontinuation, perioperative risk stratification, and postoperative resumption (Rahman et al
& Hietala, J